Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 3,890,000 shares, a growth of 6.0% from the October 31st total of 3,670,000 shares. Based on an average daily trading volume, of 493,300 shares, the short-interest ratio is currently 7.9 days.

Institutional Investors Weigh In On Aldeyra Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC lifted its stake in shares of Aldeyra Therapeutics by 280.1% in the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 48,313 shares during the last quarter. State Street Corp lifted its stake in shares of Aldeyra Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock valued at $5,249,000 after purchasing an additional 16,188 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in shares of Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after purchasing an additional 295,864 shares during the last quarter. Paloma Partners Management Co bought a new position in Aldeyra Therapeutics in the 3rd quarter worth $62,000. Finally, PDT Partners LLC bought a new position in Aldeyra Therapeutics in the 3rd quarter worth $169,000. Institutional investors and hedge funds own 59.71% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Friday, August 9th.

Aldeyra Therapeutics Trading Down 1.6 %

Shares of NASDAQ:ALDX opened at $4.82 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. Aldeyra Therapeutics has a 12-month low of $2.71 and a 12-month high of $6.55. The firm has a fifty day moving average of $5.21 and a two-hundred day moving average of $4.67.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). Equities analysts predict that Aldeyra Therapeutics will post -0.92 earnings per share for the current year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.